Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
10934 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 6003
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| ABO2203 Injection NCT07072169 · A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Rela… | Sclérose en plaques | Immunomodulation · Thérapie génique | Phase 1 | RECRUITING | The purpose of this study is to evaluate the safety, tolerability, pharmac… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| anti-CD19 UCAR-NK cells NCT05570188 · Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematolog… | Sclérose en plaques | Immunomodulation | Phase 1/2 | WITHDRAWN | It is a single-center, open-labeled, single-arm, non-randomized investigat… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| CD19-BCMA dual nanobody based CAR-T Cells NCT07451236 · CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | This is an early-stage, open-label clinical study of CD19-BCMA dual nanobo… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| CD45RA-depleted peripheral blood mononuclear cells NCT02942173 · CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-de… | Sclérose en plaques | Thérapie cellulaire | Phase 2/3 | COMPLETED | The purpose of this prospective randomized study is to determine whether i… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| huCART19-IL18 NCT04684563 · huCART19-IL18 in CD19+ Cancers | Sclérose en plaques | À vérifier | Phase 1 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and feasibility of huC… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| Calaspargase Pegol NCT05581030 · CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | The purpose of the study is to evaluate the safety and tolerability of the… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| CD19 CAR-T NCT04626726 · Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Tra… | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is an open, single-arm, phase I clinical study to evaluate efficacy a… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Chimeric Antigen Receptor T-Cell Therapy NCT06854159 · Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 2 | RECRUITING | This phase II trial tests how well odronextamab works before and after sta… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Cyclophosphamide NCT03505762 · Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B… | Sclérose en plaques | À vérifier | Phase 2 | ACTIVE_NOT_RECRUITING | This randomized phase II trial studies how well paclitaxel with or without… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Ofatumumab NCT01555541 · Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologou… | Sclérose en plaques | Remyélinisation · Thérapie cellulaire | Phase 2 | COMPLETED | This is an observational cross-sectional study of Ocrelizumab or Ofatumuma… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| R-CHOP NCT02054559 · ASPIRE — R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL | Sclérose en plaques | Immunomodulation | Phase 3 | WITHDRAWN | To compare the efficacy and safety of chemotherapy alone and combined moda… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| ST-067 NCT04787042 · Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This is a multiphase, multicenter study, which includes a Phase 1a open-la… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Aminophylline NCT07348510 · Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Car… | Sclérose en plaques | À vérifier | Non applicable | RECRUITING | This safety study is the first in a series of studies testing the applicat… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Aminophylline NCT01250496 · ASSUAGE — Study With Aminophylline to Attenuate of the Side Effects of Regadenos… | Sclérose en plaques | À vérifier | Phase 4 | TERMINATED | This safety study is the first in a series of studies testing the applicat… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Ivacaftor NCT02310789 · (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The… | Sclérose en plaques | À vérifier | Non applicable | COMPLETED | Clinical studies of lumacaftor + ivacaftor (combo therapy) produced better… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Theophylline ER NCT03984188 · Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated… | Sclérose en plaques | À vérifier | Phase 3 | COMPLETED | Pseudohypoparathyroidism is a genetic disorder with limited treatment opti… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Belatacept 250 Milligram Intravenous Powder for Solution NCT05562869 · BELASBRIDGE — Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplan… | Maladie rénale chronique | À vérifier | Phase 3 | RECRUITING | Calcineurin inhibitors (CNI) remain the standard treatment in renal transp… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
| Finerenone NCT07841015 · FINE-IMSS-MX — A Study to Learn More About How Well Finerenone Works in Real-wor… | Maladie rénale chronique | Traitement symptomatique | À vérifier | NOT_YET_RECRUITING | This study is a multicenter, double-blind, randomized, placebo-controlled… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
| KDSTEM Inj. NCT06071143 · Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease | Maladie rénale chronique | Thérapie cellulaire | Phase 1 | COMPLETED | A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
| Medium Cut-Off Dialyzer for Expanded Hemodialysis NCT07936942 · Quality of Life and Uremic Toxins in HDx | Maladie rénale chronique | À vérifier | Non applicable | COMPLETED | Expanded hemodialysis (HDx) is a dialysis treatment designed to improve th… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4910
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Association Between Geriatric Nutritional Risk Index and Gemcitabine… paclitaxel albumin-stabilized nanoparticle formulation · PMID 42373239 | Cancer | À vérifier | Publication | PubMed | Voir la publication source This retrospective study evaluated the impact of Geriatric Nutritional Risk Index (GNRI) group on time to treatment fai… | Anticancer research 2026-07-08 12:06:44 | Source |
| Nab-paclitaxel or Paclitaxel Treatment for Relapsed Small Cell Lung C… paclitaxel albumin-stabilized nanoparticle formulation · PMID 42373285 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Relapsed small cell lung cancer (SCLC) treatment has limited evidence-based options. Solvent-based paclitaxel (PTX) and… | Anticancer research 2026-07-08 12:06:44 | Source |
| Responsive stimulation of the thalamus for idiopathic generalized epi… RNS® System · PMID 42233958 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive the… | Epilepsia 2026-07-08 12:06:44 | Source |
| Thalamocortical seizure onset patterns in drug-resistant focal epilep… RNS® System · PMID 42396599 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Drug-resistant epilepsy affects tens of millions of people worldwide and is associated with considerable morbidity and… | Brain communications 2026-07-08 12:06:44 | Source |
| A review of the efficacy and safety of eslicarbazepine acetate in the… BIA 2-093 · PMID 26136845 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Eslicarbazepine acetate is a is a once-daily antiepileptic drug (AED) that was approved in 2009 by the European Medicin… | Therapeutic advances in neurological disorders 2026-07-08 12:06:42 | Source |
| K7 and K Potassium Channels in Thalamocortical Function and Their The… Effects of Antiepileptic Drugs on Brain Excitability · PMID 42261627 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Potassium (K) channels are one of the key regulators of neuronal excitability and network stability. Among all the pota… | Archiv der Pharmazie 2026-07-08 12:06:42 | Source |
| Lateral Habenula 5-HT₂A Receptors Mediate Social Deficits in a Valpro… Effects of Antiepileptic Drugs on Brain Excitability · PMID 42277370 | Épilepsie | Traitement symptomatique | Publication | PubMed | Voir la publication source Autism Spectrum Disorder (ASD) is characterized by social deficits, yet underlying neural mechanisms remain poorly unde… | Molecular neurobiology 2026-07-08 12:06:42 | Source |
| Progress report on new antiepileptic drugs: a summary of the Ninth Ei… BIA 2-093 · PMID 19008076 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source The Ninth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT IX, took place in Sitges, Barcelona from the 15th to… | Epilepsy research 2026-07-08 12:06:42 | Source |
| Diagnostic performance of [18F]FDG PET/CT in large vessel vasculitis… 18F-FDG · PMID 42411928 | Cancer · Épilepsie · Épilepsie | Immunomodulation | Publication | PubMed | Voir la publication source Large vessel vasculitis (LVV), encompassing giant cell arteritis (GCA), Takayasu arteritis (TAK) and polymyalgia rheuma… | The quarterly journal of nuclear medicine and molecula… 2026-07-08 12:06:41 | Source |
| Divergent Radiomolecular Phenotype of Spindle Cell Lipoma: Inten… 18F-FDG · PMID 42411770 | Cancer | À vérifier | Publication | PubMed | Voir la publication source A 68-year-old man with gastric cancer underwent 18F-fluorodeoxyglucose (FDG) PET/CT, which revealed an incidental subcu… | Clinical nuclear medicine 2026-07-08 12:06:41 | Source |
| Intermittent theta burst stimulation enhances the efficacy of brain-c… Intermittent theta burst stimulation · PMID 42404120 | Accident vasculaire cérébral | À vérifier | Publication | PubMed | Voir la publication source "BCI illiteracy," characterized by insufficient -rhythm Event-Related Desynchronization (ERD) in approximately 40% of s… | Frontiers in neurology 2026-07-08 12:06:40 | Source |
| Subchronic comparative assessment of graded ferrous sulfate doses on… 0.9% NaCl · PMID 42376110 | Maladie d’Alzheimer | Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Iron is a necessary trace element in the human body. However, excessive concentration can promote the overproduction of… | Open veterinary journal 2026-07-08 12:06:39 | Source |
| Sustainable soil improvement strategies for coral islands: Synergisti… 0.9% NaCl · PMID 42379437 | Maladie d’Alzheimer | À vérifier | Publication | PubMed | Voir la publication source The sustainable development of coral islands is constrained by bottleneck issues such as poor water retention and nutri… | International journal of biological macromolecules 2026-07-08 12:06:39 | Source |
| Minaxolone: an evaluation with and without premedication. Allopregnanolone injection (intravenous solution) · PMID 7270828 | Maladie d’Alzheimer | Traitement symptomatique | Publication | PubMed | Voir la publication source Minaxolone, a water-soluble steroid intravenous anaesthetic, has been used in clinical trials for induction and mainten… | Anaesthesia 2026-07-08 12:06:38 | Source |
| Continuous theta burst stimulation to the frontal pole durably decrea… Continuous theta burst stimulation · PMID 42379239 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The frontal pole is a transdiagnostic target for affective disorders, perhaps through its connectivity with affective r… | International review of psychiatry (Abingdon, England) 2026-07-08 12:06:37 | Source |
| Role of the Upper Motor Neuron in the Generation of Fasciculations in… Continuous theta burst stimulation · PMID 42407013 | Sclérose latérale amyotrophique | À vérifier | Publication | PubMed | Voir la publication source The origin of fasciculation potentials (FPs) in the early stages of amyotrophic lateral sclerosis (ALS) remains a subje… | Neurology 2026-07-08 12:06:37 | Source |
| Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatre… Levodopa/carbidopa solution for SC administration · PMID 30055367 | Maladie de Parkinson | Traitement symptomatique | Publication | PubMed | Voir la publication source Osmotic demyelination syndrome commonly follows rapid correction of hyponatremia. Although pons is a common location, e… | World neurosurgery 2026-07-08 12:06:36 | Source |
| Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson'… Levodopa/carbidopa solution for SC administration · PMID 33772855 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The aim was to demonstrate that continuous s.c. infusion of a soluble levodopa (LD)/carbidopa (CD) phosphate prodrug co… | Annals of neurology 2026-07-08 12:06:36 | Source |
| Between Surgery and Science: Patient Journeys in Deep Brain Stimulati… Determining Patterns In Trial Experiences of Parkinson's Disease Patients · PMID 41910515 | Maladie de Parkinson | Thérapie génique | Publication | PubMed | Voir la publication source For the past 25 years, local field potential (LFP) recordings from externalized deep brain stimulation (DBS) leads have… | Neuromodulation : journal of the International Neuromo… 2026-07-08 12:06:35 | Source |
| Technology Acceptance of 2 mHealth Apps During an Observational Techn… Determining Patterns In Trial Experiences of Parkinson's Disease Patients · PMID 42061832 | Maladie de Parkinson | Immunomodulation · Traitement symptomatique | Publication | PubMed | Voir la publication source Mobile health (mHealth) apps are useful tools for research and disease management. However, implementation of mHealth a… | JMIR human factors 2026-07-08 12:06:35 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||